Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Wallentin L, Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E. Wallentin L, et al. Among authors: husted s. Lancet. 2000 Jul 1;356(9223):9-16. doi: 10.1016/s0140-6736(00)02427-2. Lancet. 2000. PMID: 10892758 Clinical Trial.
Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP, Kontny F, Kempf T, Levin LÅ, Lindahl B, Stridsberg M, Ståhle E, Venge P, Wollert KC, Swahn E, Lagerqvist B; FRISC-II study group. Wallentin L, et al. Among authors: husted s. Lancet. 2016 Oct 15;388(10054):1903-1911. doi: 10.1016/S0140-6736(16)31276-4. Epub 2016 Aug 29. Lancet. 2016. PMID: 27585757 Clinical Trial.
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study.
Lagerqvist B, Husted S, Kontny F, Näslund U, Ståhle E, Swahn E, Wallentin L; Fast Revascularization during InStability in Coronary artery disease-II Investigators. Lagerqvist B, et al. Among authors: husted s. J Am Coll Cardiol. 2002 Dec 4;40(11):1902-14. doi: 10.1016/s0735-1097(02)02572-x. J Am Coll Cardiol. 2002. PMID: 12475448 Free article. Clinical Trial.
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin L; Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators. Lagerqvist B, et al. Among authors: husted s. Lancet. 2006 Sep 16;368(9540):998-1004. doi: 10.1016/S0140-6736(06)69416-6. Lancet. 2006. PMID: 16980115 Clinical Trial.
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Cannon CP, et al. Among authors: husted s. Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13. Lancet. 2010. PMID: 20079528 Clinical Trial.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators. Wallentin L, et al. Among authors: husted s. Lancet. 2010 Oct 16;376(9749):1320-8. doi: 10.1016/S0140-6736(10)61274-3. Lancet. 2010. PMID: 20801498
469 results